inno.N

Company Overview

innovate New & Next,
inno.N is making the leap towards becoming the next global bio health care company.

About inno.N

inno.N brings us closer to the long-awaited dreams of a healthier and more beautiful daily life by living up to its social responsibilities and rising up to the challenge.

innovate New & Next
We help chart
the next century.

Since its establishment in 1984, inno.N has tapped into the belief that its business was also helping chart the nation’s future. This belief has served and continues to serve the company well, as it has grown into one of the leading pharmaceutical firms in the nation.
Since its establishment in 1984, inno.N has gained competitiveness in the businesses of prescription drugs, active pharmaceutical ingredients, health supplements and beauty products.
Drawing on the company’s experience and knowhow in developing novel drugs, inno.N succeeded in launching ‘K-CAB’, the 30th novel drug to be developed and registered in Korea, to great acclaim. Building on this success, inno.N remains committed to growing into a global bio health company built on outstanding products and technologies that bring us closer to a healthier future.
  1. Year of
    establishment

    History

    1984

  2. Address

    239, Osongsaengmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do

    Location
  3. Annual
    revenue for

    2021

    7,698
    billion won

  4. Operating
    profits for

    2021

    503
    billion won

  5. Number of
    employees as of

    2021

    A total of
    1,662

Corporate PR

View more

Business Overview

inno.N’s key businesses are in the areas of prescription drugs, health supplements and beauty products. Through exports and global alliances, the company is growing into an international pharmaceutical firm.

Key businesses

Drawing on the company’s experience as a leading pharmaceutical firm of Korea and knowhow in developing a variety of high quality prescription drugs and active pharmaceutical ingredients, inno.N succeeded in launching ‘K-CAB’ to great acclaim. K-CAB is a treatment for GERD, and is also the 30th novel drug to be developed and registered in Korea. Building on this success, inno.N remains committed to becoming not only a market leader in Korea, but also a leading global bio health company.
The healthy and beauty business has also seen continuous growth, driven by Condition, the market leader for anti-hangover beverages first launched in 1992, as well as Oriental Raisin Water, a steady-seller in the market for health drinks. By offering an increasing number of health supplement and beauty products, inno.N plans to increase the future value of the company by positioning itself as a ‘health care partner’ that will join you throughout various stages in life.
  • Prescription drugs

    inno.N aims to become a global leader in supplying prescription drugs by offering high value-added products such as the blockbuster K-CAB, the biopharmaceuticals Epokine and intravenous fluids.
    Take a look at the products
  • HEALTH

    With the anti-hangover beverage ‘Condition’, the premium health supplement brand ‘Nutine’ and the health supplement beverage ‘Oriental Raisin Water (Hutgaesoo)’, inno.N helps create a more beautiful future.
    Take a look at the products
  • BEAUTY

    The derma-cosmetics brand ‘Klederma’, the brand for early anti-ageing products ‘bewants’ and the brand specializing in the treatment of hair loss and scalp health ‘Scalpmed’ help create a more beautiful future.
    Take a look at the products

Global businesses

Drawing on its global sales network and marketing capabilities that it has built up over the years, inno.N has been offering its prescription drugs, active pharmaceutical ingredients, and health and beauty products to global markets. Products are now exported to Japan, Southeast Asia and Latin America. Vietnam, in particular, serves a critical role as a market where the company is engaging in direct sales with its own sales and marketing networks to reinforce the company’s global marketing capacity.

Strategic alliances

With its specialized sales and marketing capabilities as well as strong R&D in novel and biological drugs, inno.N has been able to forge a number of strategic alliances with global pharmaceutical firms, both large and small. The alliances with multinational pharmaceutical firms, including AstraZeneca, MSD, Takeda, Eisai, Daiichi Sankyo, have allowed inno.N to make innovative drugs more widely available to the Korean market, and to export worldwide the novel drugs and biological drugs developed by inno.N, making the competitiveness of one of Korea’s leading bio and healthcare company well known around the world.
Country Partner company Products
UK Astra Zeneca Vivacor
USA Braintree K-CAB
USA MSD Gardasil, Gardasil 9, Zostavax, Prodiax, Rotateq
USA Currax Silenor
USA Lineage cell therapeutics Hextend
Japan Kureha Kremezin
Japan Kyowa Hakko Kirin Tostrex
Japan Nippon Chemiphar Soleton
Japan Sumitomo Dainippon Almarl
Japan Eisai Decaquinon
Japan Daiichi Sankyo Banan, Vitamedin, Mevalotin
Japan Mitsubishi Tanabe Herben, Arobest
Japan Takeda Madipine, Ceradoran, Basen
Japan YL Biologics EPO
Japan RaQualia K-CAB
Switzerland Helsinn Aloxi, Akynzeo
Germany Helm Procalin
Austria Ever Pemta
China NCPC EPO
China Luoxin K-CAB
Mexico Carnot K-CAB
Indonesia Kalbe K-CAB
Vietnam Vimedimex K-CAB
Philippines MPPI K-CAB
Thailand Pond's Chemical K-CAB
Singapore UITC K-CAB
Mongolia Monos K-CAB
Malaysia Pharmaniaga K-CAB
TOP